Market Signal Briefing

Immunic Inc (NASDAQ:IMUX)’s chief medical officer Dr Andreas Muehler talked with Proactive about new data presented at the ACTRIMS Forum in San Diego, highlighting findings from the company’s phase 2 CALIPER trial in progressive multiple sclerosis (MS).

Proactive: Hello, you're watching Proactive. I'm joined by Immunic Chief Medical Officer, Dr Andreas Muehler. Andreas, very good to speak with you. You've just returned from the ACTRIMS Forum in San Diego, a conference focused on multiple sclerosis research and treatment. Immunic presented new data from the CALIPER Phase 2 trial there. Can you walk us through the key takeaways, please?

Dr Andreas Muehler: Yes, hi, and great to talk to you again. I just came back from the ACTRIMS Forum meeting in San Diego. This is a North America-based meeting with experts from both the neuroscience community and clinical neurologists. So, you really look at new MS research, as well as the clinical application of trials.

We were there with a very good team — several members of the management team and members of the medical and biomarker teams. We also had a booth in the industry exhibition and were well represented overall.

We had two posters and a poster session. Both posters were about our CALIPER trial, which is a Phase 2 trial in progressive MS that we read out in mid-2023. We presented some additional data on EBV reactivation and MRI outcomes in this trial.

One of the posters focused on MRI outcomes from the CALIPER trial and findings for acute and chronic inflammatory disease activity. Can you tell us more about that, please?

I’m happy to. MS is essentially two diseases overlaid. First, there's acute inflammatory disease, driven by peripheral immune cells entering the brain and causing lesions. These lesions — called MS lesions — are usually detected with MRI, and we categorize them as gadolinium-enhancing or T2 lesions.

In our poster, we showed that Vidofludimus calcium had a reducing effect on both gadolinium-enhancing and T2 lesions. That suggests Vidofludimus calcium impacts acute inflammation in MS.

The second component of MS is chronic inflammation inside the brain — something we don’t yet fully understand. This is referred to as chronic compartmentalized inflammation. Standard MRI measures don’t detect it well, but one marker we can use is called slowly expanding lesions (SELs). These lesions slowly grow over time, often with a rim around them.

In the CALIPER trial, we found a statistically significant reduction in SELs for the 45mg dose of Vidofludimus calcium compared to placebo. That’s encouraging, showing potential efficacy on both acute and chronic inflammation.

You also presented a second poster examining the effects of Vidofludimus calcium on EBV-specific T cell receptor repertoires. Why explore this, and what does it tell us?

About three years ago, a publication clearly showed that Epstein-Barr virus (EBV) is a necessary condition for MS. It's a chronic viral infection — most people get infected early in life, and the virus stays dormant in immune cells like B cells.

There’s growing evidence that molecular mimicry may play a role — antibodies reacting to EBV might also attack the central nervous system. This could explain MS progression. So, EBV reactivation is important to study.

Vidofludimus calcium is a broad-spectrum antiviral drug, and we had preclinical evidence it reduces EBV reactivation. In the CALIPER trial, for the first time, we showed clinical evidence of reduced EBV reactivation compared to placebo.

We used T-cell receptor repertoire analysis — you could compare it to tracking the “Top 100” immune targets. Under treatment with Vidofludimus calcium, EBV antigens dropped in ranking, indicating fewer reactivations. This is an emerging area, but these results are a strong signal.

Looking ahead to 2026, how do you see the year shaping up for Immunic?

We always say internally — 2026 is the year of Immunic. After more than a decade developing this drug, we’re now approaching the readout of our Phase 3 trials in relapsing MS.

We’ll report results from two identical Phase 3 trials at the end of 2026, each enrolling over 1,100 patients — more than 3,000 individuals across the program. It's a massive effort for any company, especially a biotech. These results will support potential regulatory submissions and, possibly, product launch.

We’re very excited to finally see the outcomes of years of work.

Quotes have been lightly edited for style and clarity

Galaxy Digital Inc. (GLXY) Q4 2025 Earnings Call February 12, 2026 1:30 PM EST

Company Participants

Michael Wursthorn
Michael Novogratz - Founder, CEO & Director
Jonathan Goldowsky - Head of Investor Relations
Anthony Paquette - Chief Financial Officer

Presentation

Michael Wursthorn

All right. Sorry about that, guys. A little bit of a technical difficulty, but we finally got it going. I am the Head of Comms here at Galaxy, Mike Wursthorn. And I just want to start with a little bit of a disclaimer before we get going.

First of all, we're really excited to be hosting our latest quarterly X Spaces following our Q4 earnings. It's a great chance to connect with our retail investors and share more of what we're working on with Galaxy. And today, I'm here joined by our CEO, Mike Novogratz; and our CFO, Tony Paquette. And as always, we're going to try to answer as many questions as we can. But as usual, there are some that we won't be able to answer. So we won't be addressing nonpublic financials or other information that might be inappropriate or

[Technical Difficulty]

Michael Novogratz
Founder, CEO & Director

All right, guys, can you hear us? Sorry about this. The last few times, we seemed to have gotten this thing right. And this time, we are striking out. I hope that doesn't say a lot for the Bitcoin price action, which has also been pretty s*****. Listen, I'm going to talk to you a little bit about my macro view to start and a quick update on Galaxy, and then we're going to open up to Q&A.

This is a bear market in crypto right now. We are below every moving average. We had expected better performance last year with gold up. The Bitcoin narratives were working, and we had a good administration, yet

Palantir stock has been on a huge run the past few years.

Growth stocks helped lead the market higher for much of the past two decades. One of the hottest growth stocks of the past few years has been Palantir Technologies (PLTR +1.71%). The stock more than doubled for three straight years from 2023 through 2025, including a monstrous 340% gain in 2024.

However, with the stock pulling back to start 2026, could this be a buying opportunity?

Image source: Getty Images.

Palantir offers customers an essential AI operating system While other software-as-a-service (SaaS) stocks have struggled in the age of artificial intelligence (AI), Palantir has become one of the most important AI companies on the planet. The reason why is simple. It has been able to turn its AI platform (AIP) into an essential operating system that organizations need to make AI more useful in the real world.

Through its Foundry AIP solution, the company can gather an organization's data from a variety of sources and then organize it into an ontology and link it to real-world counterparts. These can be physical assets, like inventory, or concepts, like customer orders. This is important as AI needs clean, structured data to perform its best and avoid hallucinations. Foundry AIP then acts as an orchestration layer for third-party large language models (LLMs) to provide actionable insights based on the organization's data to help them solve real-world problems.

As a result, Palantir's platform has become the go-to solution to turn AI from theoretical to actionable. Meanwhile, with its Bootcamp go-to-market sales model, it can show organizations how to create AI-driven tools based on their actual data in as little as five days. This type of demonstration is helping shorten sales cycles and get new commercial customers to quickly commit. Meanwhile, once Palantir lands a customer, they tend to quickly expand their usage.

Today's Change

(

1.71

%) $

2.21

Current Price

$

131.34

Palantir's success can be seen in its numbers. The company has seen its revenue growth accelerate for 10 consecutive quarters, with revenue surging 70% last quarter. Meanwhile, U.S. commercial customer revenue soared 137% as more companies adopt AIP and existing customers expand. In the fourth quarter (Q4), its customer count jumped 34%, while its net revenue retention, which measures revenue growth from existing customers that have been with the company for the past 12 months, was a robust 139%.

The one knock on Palantir is valuation, as the stock trades at a forward price-to-sales (P/S) ratio of 47 times 2026 analyst revenue estimates. That's pricey, but Palantir is one of the best growth stories in AI and is quickly growing into its valuation. While its current valuation gives me pause, I'd be a buyer on any sustained weakness in the stock price, given the position Palantir has established in the AI landscape.

Geoffrey Seiler has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Palantir Technologies. The Motley Fool has a disclosure policy.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of ALAB either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Offered by a leading investment firm, this exchange-traded fund provides adequate exposure to the American economy.

When it comes to the stock market, one clear benchmark gets most of the attention. That makes sense, given that it represents about 80% of the entire value of U.S. equities.

I'm talking about the S&P 500 index. It has historically been a superb tool to build wealth. And investors can gain exposure through exchange-traded funds (ETF).

Here's the best one to buy with $500 right now.

Image source: Getty Images.

Concentrated diversification As the name suggests, the S&P 500 contains 500 or so large and profitable companies that trade on U.S. stock exchanges. Buying the Vanguard S&P 500 ETF (VOO +0.06%), which currently has $1.5 trillion in assets under management, is a smart way to get access. Investors are basically putting their money behind the belief that the American economy will continue growing in the future.

All sectors are represented. At one end of the spectrum, there are materials and real estate, which account for a tiny share of the portfolio.

On the other side, there's the information technology sector. Companies that operate in related industries have generally registered strong growth in the past decade. Technology is clearly a significant contributor to the U.S. economy these days.

It should come as no surprise that the "Magnificent Seven" stocks make up 35% of the Vanguard S&P 500 ETF combined. There might be hundreds of businesses in this investment vehicle, but there is heavy concentration at the top. That setup isn't necessarily a bad thing. It's just critical that investors take the time to understand what they own. You should be bullish on tech-driven trends, such as artificial intelligence, if you buy this ETF.

Today's Change

(

0.06

%) $

0.40

Current Price

$

626.89

The best investors think in terms of decades Owning the Vanguard S&P 500 ETF is a hassle-free approach. What's more, the low expense ratio of 0.03% makes for an extremely compelling proposition. Investors will keep more of their money over time.

Performance is another area of focus. In the past decade, this ETF has generated a total return of 343% (as of Feb. 9). This gain would've turned a starting $10,000 into more than $44,000 today. This is much better than the S&P 500's long-term historical average of 10%.

It's impossible to predict what the future will bring. The bears will point to the stock market's expensive valuation as a signal that returns going forward won't resemble the recent past.

There are also bulls who believe the good times will continue. Instead of trying to take a stance, investors should focus on allocating capital with a time horizon that spans decades. The market should reward these folks.

Neil Patel has positions in Vanguard S&P 500 ETF. The Motley Fool has positions in and recommends Vanguard S&P 500 ETF. The Motley Fool has a disclosure policy.

New York, New York--(Newsfile Corp. - February 14, 2026) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that it has filed a class action lawsuit against Ardent Health, Inc. (NYSE: ARDT) and certain of the Company's senior executives for securities fraud after a significant stock drop resulting from potential violations of the federal securities laws.

If you invested in Ardent Health, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ardent-health-inc-class-action-lawsuit.

Investors have until March 9, 2026, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Ardent Health securities. The class action is pending in the U.S. District Court for the Middle District of Tennessee. It is captioned Postiwala v. Ardent Health, Inc., et al., No. 3:26-cv-00022.

Why is Ardent Health Being Sued for Securities Fraud?

Ardent Health and its affiliates operate acute care hospitals and other healthcare facilities. A critical aspect of Ardent Health's operations is the collection of accounts receivable and the framework by which Ardent Health determines the collectability of such accounts. According to the lawsuit, Ardent Health stated that it employed an active monitoring process to determine the collectability of its accounts receivable, and that this process included "detailed reviews of historical collections" as a "primary source of information."

As alleged, in truth, Ardent Health did not primarily rely on "detailed reviews of historical collections" in determining collectability of accounts receivable, but instead "utilized a 180-day cliff at which time an account became fully reserved." This allowed Ardent Health to report higher amounts of accounts receivable during the Class Period, and delay recognizing losses on uncollectable accounts. The lawsuit alleges that Ardent Health's purported misrepresentations are a violation of the federal securities laws.

Why did Ardent Health's Stock Drop?

On November 12, 2025, after market hours, Ardent Health revealed it had completed "hindsight evaluations of historical collection trends" that resulted in a $43 million decrease in revenue for the quarter. Ardent Health also revealed that it increased its professional liability reserves by $54 million because of "adverse prior period claim developments" resulting from a set of claims between 2019 and 2022 "as well as consideration of broader industry trends."

This news caused the price of Ardent Health stock to drop $4.75 per share, or more than 33%, from a closing price of $14.05 per share on November 12, 2025, to $9.30 per share on November 13, 2025.

Click here for more information: https://www.bfalaw.com/cases/ardent-health-inc-class-action-lawsuit.

What Can You Do?

If you invested in Ardent Health, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/ardent-health-inc-class-action-lawsuit

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, "Litigation Stars" by Benchmark Litigation, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360 and "SuperLawyers" by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/ardent-health-inc-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/283764

Source: Bleichmar Fonti & Auld

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

New York, New York--(Newsfile Corp. - February 14, 2026) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Fermi Inc. (NASDAQ: FRMI), certain of the Company's senior executives and directors, and underwriters of Fermi's Initial Public Offering after a significant stock drop resulting from potential violations of the federal securities laws.

If you invested in Fermi, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/fermi-inc-class-action-lawsuit.

Investors have until March 6, 2026, to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Fermi securities, as well as claims under Sections 11 and 15 of the Securities Act of 1933 on behalf of investors who purchased or acquired Fermi common stock pursuant and traceable to the Company's Initial Public Offering. The case is pending in the U.S. District Court for the Southern District of New York and is captioned Lupia v. Fermi Inc., et al., No. 1:26-cv-00050.

Why is Fermi Being Sued for Violations of the Federal Securities Laws?

Fermi is an energy and AI infrastructure company that purportedly intends to build multiple, large scale nuclear reactors to support its own network of large, grid-independent data centers powered by nuclear and other energy to power AI companies. Fermi's first project is Project Matador, its flagship, first-of-its kind energy and AI infrastructure campus designed to provide dedicated power for AI workloads.

Fermi completed its IPO in October 2025. In the IPO Registration Statement, Fermi represented that it "entered into a letter of intent . . . with an investment grade-rated tenant (the 'First Tenant') to lease a portion of the Project Matador Site . . . for an initial lease term of twenty years." The Company also represented there was strong demand for Project Matador and that construction of the facility would be funded by "tenant payments" and "lease agreements." Following the IPO, Fermi announced that the First Tenant entered into an Advance in Aid of Construction Agreement, through which it would advance up to $150 million to Fermi to fund Project Matador construction costs.

As alleged, in truth, Fermi overstated tenant demand for Project Matador and misrepresented the agreement with the First Tenant.

Why did Fermi's Stock Drop?

On December 12, 2025, Fermi disclosed that "[o]n December 11, 2025, the First Tenant notified the Company that it is terminating the [Advance of Aid of Construction Agreement]" after "[t]he exclusivity period set forward in the letter of intent expired." Fermi also stated that it had "commenced discussions with several other potential tenants" and "continue[s] to negotiate the terms of a lease agreement at Project Matador" with the First Tenant. This news caused the price of Fermi stock to drop $5.16 per share, or more than 33%, from a closing price of $15.25 per share on December 11, 2025, to $10.09 per share on December 12, 2025.

Click here for more information: https://www.bfalaw.com/cases/fermi-inc-class-action-lawsuit.

What Can You Do?

If you invested in Fermi, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/fermi-inc-class-action-lawsuit

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, "Litigation Stars" by Benchmark Litigation, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360 and "SuperLawyers" by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/fermi-inc-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/283768

Source: Bleichmar Fonti & Auld

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Key Takeaways Palo Alto Networks is slated to post fiscal second-quarter earnings on Tuesday afternoon, with analysts calling for growing revenue and profits.Options pricing suggests traders expect the stock could move up to 8% in either direction by the end of the week following the results. Palo Alto Networks is set to report earnings after the closing bell Tuesday, with traders anticipating a big move from the cybersecurity firm's stock in the wake of the results.

Options pricing suggests traders expect Palo Alto Networks (PANW) stock could move up to 8% in either direction by the end of the week following the report. A move of that size from Friday close near $167 could bring the stock back above $180 at the high end, reversing some of its slump from October highs. At the low end, the stock could sink to $153.

Despite logging gains over the past week, Palo Alto Networks shares have had a rough start to this year, as cybersecurity stocks took a hit amid a broader rout in software. The company's shares are down 9% for 2026 so far, and nearly 25% off their October record.

Why This Matters to Investors The growing capabilities of AI have also introduced new security threats, boosting demand for Palo Alto Networks' cybersecurity offerings in recent quarters. Investors and analysts will likely be watching what the company's latest results Tuesday could say about industry trends.

William Blair analysts said ahead of the report that investors will also likely be looking for updates on Palo Alto Networks' plans regarding its recent acquisitions. On Wednesday, the company said that it completed its $25 billion deal for CyberArk. Palo Alto Networks last month also closed its acquisition of AI cybersecurity firm Chronosphere, which was announced alongside last quarter's earnings in November.

Palo Alto Networks is seen reporting adjusted earnings per share of 94 cents on a 14% year-over-year jump in revenue to $2.58 billion for its fiscal second quarter, according to estimates compiled by Visible Alpha.

Wall Street analysts are widely bullish on the stock. Of the 14 analysts with current ratings tracked by Visible Alpha, 10 recommend buying the stock, compared to four neutral ratings. Their average price target at $218 would suggest about 30% upside from Friday's close.

Do you have a news tip for Investopedia reporters? Please email us at

[email protected]

New York, New York--(Newsfile Corp. - February 14, 2026) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Plug Power Inc. (NASDAQ: PLUG) and certain of the Company's senior executives for securities fraud after significant stock drops resulting from the potential violations of the federal securities laws.

If you invested in Plug Power, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/plug-power-class-action-lawsuit.

Investors have until April 3, 2026, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Plug Power securities. The case is pending in the U.S. District Court for the Northern District of New York and is captioned Ortolani v. Plug Power Inc., et al., No. 1:26-cv-00165.

Why is Plug Power Being Sued for Securities Fraud?

Plug Power provides hydrogen fuel cell turnkey solutions for the electric mobility and stationary power markets and develops infrastructure such as hydrogen production plants. During the relevant period, Plug Power announced it had "closed a $1.66 billion loan guarantee" from the U.S. Dept. of Energy's Loan Program Office to "help finance the construction of up to six projects to produce and liquefy zero- or low-carbon hydrogen at scale throughout the United States."

As alleged, in truth, Plug Power materially overstated the likelihood that DOE loan funds would ultimately become available to Plug Power, and that Plug Power would ultimately construct the hydrogen production facilities necessary to receive those funds.

Why did Plug Power's Stock Drop?

On October 7, 2025, Plug Power announced the abrupt departure of its CEO, Andrew Marsh, and its President, Sanjay Shrestha. This news caused the price of Plug Power stock to drop $0.26 per share, or 6.3%, from a closing price of $4.13 per share on October 6, 2025, to $3.87 per share on October 7, 2025.

A month later, on November 10, 2025, Plug Power announced that it "suspended activities under the DOE loan program," which purportedly allowed the Company to "redeploy capital" to pursue an agreement with a U.S. data center developer to monetize electricity rights. This news caused the price of Plug Power stock to drop $0.09 per share, or 3.4%, from a closing price of $2.65 per share on November 7, 2025, to $2.56 per share on November 10, 2025, the next trading day.

Then, on November 13, 2025, The Washington Examiner reported that Plug Power "confirmed . . . that it suspended activities" on "its plans to construct six facilities to produce and liquefy zero or low-carbon hydrogen, putting at risk" the $1.66 billion DOE loan it closed in January. This news caused the price of Plug Power stock to drop $0.48 per share, or 17.6%, from a closing price of $2.49 per share on November 13, 2025, to $2.25 per share on November 14, 2025.

Click here for more information: https://www.bfalaw.com/cases/plug-power-class-action-lawsuit.

What Can You Do?

If you invested in Plug Power, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/plug-power-class-action-lawsuit

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, "Litigation Stars" by Benchmark Litigation, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360 and "SuperLawyers" by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/plug-power-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/283771

Source: Bleichmar Fonti & Auld

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Accenture just paid shareholders $1.63 per share on February 13, 2026, marking the latest installment in a 20+ year streak of consecutive annual dividend increases. But with the stock down 41% over the past year and trading at $224.08, investors need to look beyond the growth streak to understand whether this 2.6% yielder still deserves a place in dividend portfolios.

The Dividend Growth Story Remains Intact Accenture’s dividend trajectory tells a story of disciplined capital allocation. The consulting giant increased its quarterly payout from $1.48 to $1.63 starting in the third quarter of fiscal 2025, representing a 10.1% increase. On an annualized basis, shareholders now collect $6.22 per share, up from $5.54 the prior year-a 12.1% year-over-year increase.

The longer-term growth rates underscore the company’s commitment. Over five years, Accenture’s dividend has climbed 85.1%, and the 10-year growth rate stands at an impressive 510.8%. This consistency matters: Accenture has raised its dividend every year for more than two decades, placing it among the technology sector’s most reliable income generators.

Cash Flow Coverage Provides Substantial Safety Margin The sustainability of Accenture’s dividend rests on robust cash generation. In fiscal 2025, the company produced $11.47 billion in operating cash flow, up from $9.13 billion the prior year. After subtracting $600 million in capital expenditures, free cash flow reached $10.87 billion.

Against total dividend payments of $3.70 billion, Accenture’s free cash flow covered the dividend 2.94 times, providing a comfortable cushion that leaves ample room for dividend growth even if business conditions soften. The company’s capital intensity remains low, with capex consuming just 5.2% of operating cash flow, a characteristic that distinguishes professional services firms from capital-heavy industrials.

The traditional payout ratio tells a similar story. With trailing twelve-month earnings of $11.57 per share and an annualized dividend of $6.22, Accenture’s payout ratio sits at 53.8%-well below the 60-70% threshold that typically signals limited room for growth. For context, IBM pays out 60.2% of earnings as dividends while growing its payout at just 3.6% annually over the past decade.

The Valuation Disconnect Here’s where Accenture’s dividend story gets complicated. The stock trades at 20 times trailing earnings, down from a 52-week high of $383.40. Analysts maintain a $292.42 average target price, suggesting 30% upside from current levels, yet the stock has dramatically underperformed the broader market.

While the S&P 500 gained 14.8% over the past year, Accenture shareholders endured a 41% decline. Over five years, the stock is down 5.6% while the S&P 500 surged 76.5%. Even the dividend hasn’t offset this underperformance-total returns including reinvested dividends would still trail the index significantly.

The disconnect stems from concerns about Accenture’s growth trajectory. Fourth quarter fiscal 2025 revenue of $17.60 billion grew 7.3% year-over-year, but management’s fiscal 2026 guidance calls for just 2-5% revenue growth in local currency. That deceleration has investors questioning whether the company can maintain its premium valuation as traditional IT services spending slows.

Recent Wins and Strategic Positioning Despite the stock’s struggles, Accenture continues winning major contracts that could support future dividend growth. The company recently secured a position on the U.S. Department of Veterans Affairs Electronic Health Record Modernization program, a multi-billion dollar mandate that reinforces its standing as a preferred partner for large-scale digital transformations.

In January, Accenture Federal Services won a $1.4 billion task order to modernize the Army Corps of Engineers’ cybersecurity system, though competitor SAIC has challenged the award. The company has also partnered with Palantir Technologies on sovereign AI data centers in EMEA, positioning itself in the high-growth artificial intelligence infrastructure market.

UBS analysts identify Accenture as a key beneficiary of increased generative AI spending, noting that enterprises are ramping up consulting budgets to implement AI capabilities. The firm maintains strong profitability with a 10.8% profit margin and 25% return on equity.

Capital Allocation Beyond the Dividend Accenture doesn’t just return cash through dividends. The company repurchased $4.62 billion of stock in fiscal 2025, bringing total shareholder returns to $8.32 billion-roughly 71.6% of operating cash flow. This aggressive buyback program has helped offset dilution from stock-based compensation while supporting earnings per share growth even as revenue growth moderates.

The company ended its most recent quarter with $11.48 billion in cash and maintains a $5 billion share buyback authorization. This financial flexibility provides management with options to accelerate buybacks if the stock remains depressed or to pursue strategic acquisitions that could reignite growth.

What the Dividend Scorecard Shows Institutional investors continue backing Accenture despite the stock’s weakness. ING Groep recently increased its stake by 219.3%, bringing its position to 141,196 shares valued at $34.8 million. The analyst community maintains a moderate buy rating, with 3 strong buy ratings, 13 buy ratings, 11 hold ratings, and just 1 sell rating.

This Accenture (ACN) dividend scorecard provides an overall ‘A’ grade based on strong fundamentals, though it notes recent stock underperformance. Wall Street analysts currently rate ACN a “Moderate Buy” for long-term income investors as of February 12, 2026. The dividend itself scores well on sustainability metrics but faces questions on total return potential. The 20+ year growth streak and 2.94 times cash flow coverage earn high marks for safety and consistency. The 2.6% current yield sits above the S&P 500 average but trails other technology dividend payers like IBM’s 2.3%.

Where Accenture stumbles is in capital appreciation. A dividend growth rate of 12.1% looks impressive until you consider the stock’s 41% decline over the past year. Investors who bought Accenture for income a year ago have seen their total position value drop substantially despite receiving growing dividend checks.

The Path Forward Accenture’s dividend remains on solid footing. The company generates ample cash flow, maintains conservative payout ratios, and operates in markets-AI consulting, digital transformation, cybersecurity-that should support long-term growth. Management has demonstrated unwavering commitment to the dividend through two decades of increases, including during the 2008 financial crisis and COVID-19 pandemic.

The challenge lies in valuation and growth expectations. At current prices, Accenture offers a forward P/E of 17.5 based on fiscal 2026 guidance of $13.19-$13.57 in earnings per share. That’s reasonable for a business with strong returns on capital and a growing dividend, but only if revenue growth reaccelerates beyond the 2-5% guided range.

For dividend-focused investors, Accenture presents a nuanced case. The dividend itself deserves a solid B+ grade: safe, growing, and backed by strong fundamentals. But total return prospects depend on whether the company can prove that generative AI consulting revenues will offset weakness in traditional IT services spending. The next few quarters will determine whether this dividend grower can also deliver the stock price appreciation that income investors need to achieve their overall return objectives.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Mereo BioPharma To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Mereo between June 5, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Feb. 14, 2026 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Mereo BioPharma Group plc (“Mereo” or the “Company”) (NASDAQ: MREO) and reminds investors of the April 6, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose the true state of the Phase 3 ORBIT and COSMIC programs; neither of which hit its primary endpoints of reducing annualized clinical fracture rate compared to the placebo or bisphosphonate control groups, respectively.

Mereo announced during pre-market hours on December 29, 2025, that two Phase 3 studies of setrusumab failed to meet their primary endpoints of reducing annualized clinical fracture rates versus placebo and bisphosphonates, respectively. While both trials demonstrated statistically significant improvements in bone mineral density on secondary endpoints and no new safety concerns were identified, the market reacted negatively to the primary endpoint misses.

On this news, Mereo’s stock price fell $2.02 per share, or 87.64%, closing at $0.28 per share on December 29, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.  

Faruqi & Faruqi, LLP also encourages anyone with information regarding Mereo BioPharma’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Mereo BioPharma class action, go to www.faruqilaw.com/MREO or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c00df434-1b43-4881-800b-4385df9e694a

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In F5 To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in F5 between October 28, 2024 and October 27, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Feb. 14, 2026 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against F5, Inc. (“F5” or the “Company”) (NASDAQ: FFIV) and reminds investors of the February 17, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that the true state of F5’s security capabilities; notably, that it was not truly equipped to safely secure data for its clients as F5 itself was, for all relevant times, experiencing a significant security breach (the “Security Breach”) of some of its key offerings and, further, that the revelation of this breach would significantly impact F5’s potential to capitalize on the security market.

On October 27, 2025, F5 announced their fourth quarter fiscal year 2025 results after the market closed, providing significantly below-market growth expectations for fiscal 2026 due in significant part to the Security Breach as the Company announced expected reductions to sales and renewals, elongated sales cycles, terminated projections, and increased expenses attributed to ongoing remediation efforts. Pertinently, defendants also disclosed that BIG-IP, the product that was the subject of the Security Breach, is the company’s highest revenue product, elevating the scope of the impact from the original disclosure as F5 does not otherwise provide revenue contributions by product line.

Following this news, the price of F5’s common stock declined dramatically. From a closing market price of $290.41 per share on October 27, 2025, F5’s stock price fell to $258.76 per share on October 29, 2025, a decline of an additional 10.9% in the span of two days.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.  

Faruqi & Faruqi, LLP also encourages anyone with information regarding F5’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the F5 class action, go to www.faruqilaw.com/FFIV or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c00df434-1b43-4881-800b-4385df9e694a

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In BellRing To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in BellRing between November 19, 2024 and August 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Feb. 14, 2026 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against BellRing Brands, Inc. (“BellRing” or the “Company”) (NYSE: BRBR) and reminds investors of the March 23, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose the strength, sustainability, and drivers of BellRing’s sales growth, as well as the impact of competition on the demand for the Company’s products.

On May 5, 2025, after market hours, BellRing revealed that starting in Q2 2025, "several key retailers lowered their weeks of supply on hand," which would create a headwind to Q3 2025 growth. The Company also announced it was expanding promotions to boost sales and "offset [] third quarter reductions in retailer trade inventory levels."

On this news, the price of BellRing stock declined $14.88 per share, or 19%, from $78.43 per share on May 5, 2025, to close at $63.55 per share on May 6, 2025, on unusually heavy trading volume.

Then, on August 4, 2025, after market hours, BellRing announced disappointing quarterly consumption of Premier Protein RTD Shakes, which had been expected to outpace shipments by a wider margin given previously announced retailer destocking, but instead came "more in line" with shipments.

On this news, the price of BellRing Brands stock fell $17.46 per share, or nearly 33%, from $53.64 per share on August 4, 2025, to $36.18 per share on August 5, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.  

Faruqi & Faruqi, LLP also encourages anyone with information regarding BellRing’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the BellRing Brands class action, go to www.faruqilaw.com/BRBR or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fee60b7b-e6c3-458d-b56d-abc6af902c49

Peter Zhang Feb 14, 2026 10:31

Litecoin shows signs of stabilization at $55.44 with technical indicators suggesting a potential recovery toward $65-70 range by March, though bears remain in control short-term.

Litecoin (LTC) has demonstrated resilience with a 3.94% gain in the past 24 hours, currently trading at $55.44. Despite the recent uptick, the cryptocurrency remains well below its key moving averages, presenting both challenges and opportunities for traders looking ahead.

LTC Price Prediction Summary • Short-term target (1 week): $57-59 • Medium-term forecast (1 month): $62-68 range
• Bullish breakout level: $70.81 (Upper Bollinger Band) • Critical support: $51.88

What Crypto Analysts Are Saying About Litecoin Recent analyst commentary from Timothy Morano and Ted Hisokawa in early January suggested LTC price prediction targets in the $87-95 range, contingent on maintaining the $82 support level. However, with Litecoin currently trading significantly below these levels at $55.44, these bullish projections appear overly optimistic in the near term.

According to on-chain data and technical analysis platforms, Litecoin's current positioning suggests a more measured recovery approach is likely. The cryptocurrency needs to reclaim several key resistance levels before any substantial upward momentum can be sustained.

LTC Technical Analysis Breakdown The current technical picture for Litecoin presents a mixed but cautiously optimistic outlook:

RSI Analysis: At 36.80, Litecoin's RSI sits in neutral territory, suggesting the cryptocurrency is neither oversold nor overbought. This provides room for upward movement without immediate resistance from momentum indicators.

MACD Signals: The MACD histogram at 0.0000 indicates bearish momentum has stalled, though a clear bullish crossover has yet to materialize. The MACD line at -4.6119 matches the signal line, suggesting a potential turning point.

Bollinger Bands Position: Trading at 0.3586 within the Bollinger Bands range, LTC sits closer to the lower band ($46.85) than the upper band ($70.81), indicating potential for upward movement toward the middle band at $58.83.

Moving Average Resistance: The cryptocurrency faces significant headwinds from multiple moving averages acting as resistance levels, particularly the SMA 20 at $58.83 and SMA 50 at $69.43.

Litecoin Price Targets: Bull vs Bear Case Bullish Scenario In the bullish case for this Litecoin forecast, LTC could target the $65-70 range by March 2026. Key levels to watch include:

Immediate resistance at $57.58 must be cleared for sustained upward momentum Breaking above the SMA 20 at $58.83 would signal renewed buyer interest Reclaiming $70.81 (Upper Bollinger Band) could trigger a move toward $75-80 This scenario requires sustained buying pressure and broader crypto market support, particularly if Bitcoin maintains its current trajectory.

Bearish Scenario The bearish case sees LTC testing lower support levels if current momentum fails:

Strong support at $51.88 represents the next critical level A break below $50 could trigger selling toward the lower Bollinger Band at $46.85 Further weakness could test the $40-45 range, representing significant downside risk Risk factors include continued selling pressure from long-term holders and broader market uncertainty affecting altcoin sentiment.

Should You Buy LTC? Entry Strategy Based on current technical analysis, potential entry strategies include:

Conservative Approach: Wait for a clear break above $58.83 (SMA 20) with volume confirmation before establishing positions. This reduces the risk of catching a falling knife while still capturing the majority of any upward move.

Aggressive Approach: Current levels around $55.44 offer a reasonable risk-reward ratio for those willing to accept higher volatility. Set stop-losses below $51.88 to limit downside exposure.

Dollar-Cost Averaging: Given the uncertain technical picture, systematic buying on dips below $54 could prove effective for long-term holders.

Risk management remains crucial, with position sizing appropriate to individual risk tolerance and overall portfolio allocation.

Conclusion This LTC price prediction suggests a cautiously optimistic outlook for Litecoin over the coming months. While short-term volatility is expected, the combination of oversold conditions and stabilizing momentum indicators supports a potential recovery toward the $65-70 range by March 2026.

The confidence level for this Litecoin forecast is moderate, given the mixed technical signals and challenging resistance levels ahead. Traders should monitor the critical $58.83 level closely, as a sustained break above this threshold would significantly improve the bullish case.

Disclaimer: Cryptocurrency price predictions are inherently speculative and subject to extreme volatility. This analysis is for informational purposes only and should not be considered financial advice. Always conduct your own research and consider your risk tolerance before making investment decisions.

Image source: Shutterstock

ltc price analysis ltc price prediction

James Ding Feb 14, 2026 10:37

Recent analyst forecasts suggest TRON could reach $0.32-$0.35 within 30 days, though current technical indicators show mixed signals at $0.28 support. TRX Price Prediction Summary • Short-term tar...

Recent analyst forecasts suggest TRON could reach $0.32-$0.35 within 30 days, though current technical indicators show mixed signals at $0.28 support.

TRX Price Prediction Summary • Short-term target (1 week): $0.29 • Medium-term forecast (1 month): $0.32-$0.35 range
• Bullish breakout level: $0.30 • Critical support: $0.27

What Crypto Analysts Are Saying About TRON Recent analyst commentary provides insight into TRON's potential trajectory. Peter Zhang noted on January 17, 2026: "TRON shows bullish momentum with RSI at 68.95 and price testing $0.31 resistance. Technical analysis suggests TRX could reach $0.32-$0.35 range within 30 days if key breakout occurs."

This sentiment was echoed by Luisa Crawford on January 27, 2026, who stated: "TRON (TRX) consolidates at $0.29 with neutral momentum. Technical analysis suggests potential upside to $0.32-$0.35 range within 30 days as multiple resistance levels align."

Felix Pinkston also provided a similar TRON forecast on January 25, 2026: "TRON (TRX) trades at $0.30 with neutral RSI at 47. Technical analysis suggests potential upside to $0.32-$0.35 range within the next month based on recent analyst forecasts."

The consensus among these analysts points to a TRX price prediction targeting the $0.32-$0.35 range, though current market conditions have shifted since these forecasts were made.

TRX Technical Analysis Breakdown TRON's current technical picture presents a mixed outlook at $0.28. The RSI reading of 45.43 indicates neutral momentum, neither oversold nor overbought, suggesting room for movement in either direction.

The MACD histogram sits at 0.0000, indicating bearish momentum has stalled but hasn't yet turned bullish. This neutral positioning could signal an impending directional move for TRX.

Bollinger Bands show TRX trading at a %B position of 0.4527, placing it below the middle band but not at extreme levels. The upper band at $0.30 represents immediate resistance, while the lower band at $0.27 provides downside support.

Moving averages paint a concerning picture with TRX trading below most key levels. The 50-day SMA at $0.29 and 200-day SMA at $0.31 both sit above current price, creating overhead resistance that could limit upside momentum.

TRON Price Targets: Bull vs Bear Case Bullish Scenario In an optimistic scenario, TRX needs to reclaim the $0.30 Bollinger Band upper resistance to validate the analyst predictions. A successful break above this level could target the $0.32-$0.35 range forecasted by multiple analysts.

Key technical confirmation would come from RSI breaking above 50 and MACD turning positive. The 24-hour trading volume of $49.69 million on Binance shows decent liquidity to support such a move.

The bullish case relies on TRX reclaiming its 50-day SMA at $0.29 as support, which would align with the analyst targets and provide a foundation for further gains toward $0.35.

Bearish Scenario The bearish case for this TRX price prediction centers on the strong support at $0.27 failing to hold. A break below this Bollinger Band lower level could trigger selling pressure toward the next significant support.

Current positioning below multiple moving averages suggests the path of least resistance remains downward. The MACD's bearish momentum, while stalled, hasn't yet turned positive, indicating underlying weakness.

Risk factors include broader crypto market sentiment and potential profit-taking if TRX fails to break above the $0.30 resistance level convincingly.

Should You Buy TRX? Entry Strategy Based on current technical levels, a conservative entry strategy would involve waiting for TRX to reclaim $0.29 support with volume confirmation. This would align with the 50-day moving average and provide better risk-reward positioning.

Aggressive traders might consider accumulating near the $0.27 support level, but this approach carries higher risk given the current technical setup. Stop-loss levels should be placed below $0.26 to limit downside exposure.

For those following the analyst TRON forecast targeting $0.32-$0.35, dollar-cost averaging between $0.27-$0.29 could provide a balanced approach while managing risk through position sizing.

Conclusion The TRX price prediction landscape shows cautious optimism despite mixed technical signals. While multiple analysts forecast a move to $0.32-$0.35 within 30 days, current price action at $0.28 requires careful monitoring of key support and resistance levels.

The neutral RSI and stalled MACD suggest TRX is at an inflection point, with the next significant move likely determining whether the bullish analyst targets remain achievable. Traders should focus on the $0.30 breakout level as confirmation of upward momentum toward the forecasted range.

This TRX price prediction is for educational purposes only and should not be considered financial advice. Cryptocurrency investments carry significant risk, and past predictions do not guarantee future results.

Image source: Shutterstock

trx price analysis trx price prediction

United States Rep. Byron Donalds has released a new financial disclosure showing a cryptocurrency purchase at a time when digital asset markets have been under pressure.

The filing lists a Bitcoin (BTC) purchase valued between $1,001 and $15,000, recorded on January 8, 2026, and publicly disclosed on February 12. This trade coincides with a period when Bitcoin has been struggling to hold key support levels, currently trading below the $70,000 spot. 

Alongside the Bitcoin purchase, the disclosure shows partial sales of traditional stocks, including Howmet Aerospace (NYSE: HWM), Parker-Hannifin Corporation (NYSE: PH), and The Trade Desk (NASDAQ: TTD), all reported in late January.

Byron Donalds’ trade transactions. Source: House Clerk Indeed, his transactions are likely to continue raising questions about his Congress trades, given that the lawmaker is a member of the House Financial Services Committee.

Receive Signals on US Congress Members' Stock Trades

Stocks

Stay up-to-date on the trading activity of US Congress members. The signal triggers based on updates from the House disclosure reports, notifying you of their latest stock transactions.

Donalds stock trade controversy  The latest filing follows earlier controversy surrounding Donalds’ cryptocurrency and stock trades while in office. In late 2025, reports noted that he and his wife purchased Bitcoin on the same day he and other lawmakers sent a letter to the Internal Revenue Service seeking changes to crypto tax rules, raising questions about the timing, given his involvement in digital asset policy.

His stock trading history has also drawn scrutiny. In this line, a nonpartisan watchdog group filed a complaint with the Office of Congressional Ethics alleging that Donalds and his spouse failed to timely disclose more than 100 stock trades worth up to about $1.6 million in 2022 and 2023, potentially violating the Stop Trading on Congressional Knowledge Act, which requires members of Congress to report transactions within 45 days.

The complaint further noted that several of the undisclosed trades involved companies overseen by the House Financial Services Committee, fueling concerns about potential conflicts of interest when lawmakers invest in sectors they help regulate.

Although no enforcement actions or legal findings have been tied to his Bitcoin or stock transactions, the pattern of high-profile trades, their proximity to policy activity, and prior ethics complaints have kept his investment activity under scrutiny.

Over the past decade, Bitcoin has consistently been the top-performing asset in the world.

When it comes to cryptocurrencies with millionaire-maker potential, one name stands alone: Bitcoin (BTC +4.18%).

According to The Crypto Wealth Report 2025 from Henley & Partners, there are 145,100 Bitcoin millionaires in the world right now. That's far more than for any other cryptocurrency. There's simply no other cryptocurrency with the same historical track record as Bitcoin or the same type of projected upside potential.

Historical track record Let's start with Bitcoin's historical track record, which is unparalleled. In 10 of the 14 years between 2012 and 2025, Bitcoin was the top-performing asset in the world, and it wasn't even close. In seven of those years, Bitcoin delivered a triple-digit performance.

For good reason, then, Bitcoin's price growth has been nearly exponential. Bitcoin traded for a price of $10 back in June 2011. Over the next 14 years, that $10 transformed into a price of $100,000. In October 2025, the world's most popular cryptocurrency traded as high as $126,000.

Today's Change

(

4.18

%) $

2791.57

Current Price

$

69612.00

Of course, Bitcoin has had some losing years along the way. In 2014, 2018, and 2022, Bitcoin posted colossal losses of more than 57%. But Bitcoin has never had back-to-back negative years. It has proven surprisingly resilient, which has made it a favorite of both retail and institutional investors.

Yes, Bitcoin lost 64% of its value in 2022. But it bounced back with triple-digit performances in both 2023 and 2024, more than making up for past transgressions. The same is likely to happen in 2027 if Bitcoin continues its losing streak in 2026.

Future potential upside Of course, past historical performance is no guarantee of future performance. Bitcoin has been so off-the-charts impressive over the past decade that it almost seems impossible to expect an encore performance over the next decade.

Image source: Getty Images.

But many investors are expecting exactly that. Amongst high-profile crypto industry insiders, the growing consensus is that Bitcoin will hit a price of $1 million by the year 2030, if not sooner. That implies a compound annual growth rate (CAGR) of 70%, given its current price of $70,000. Yes, that's an aggressive estimate, but it's really just par for the course for Bitcoin, which doubles in value with astonishing frequency.

What if this time around is different? There are no guarantees with crypto. Ever since Bitcoin hit a price of $100,000 back in December 2024, it has had trouble maintaining this stratospheric price level. There are a number of possible explanations for this, but the most likely one is that Bitcoin is once again following its four-year cycle of boom and bust.

For Bitcoin, three boom years are typically followed by one bust year before the cycle renews yet again. This has happened in 2014, 2018, and 2022. If this pattern continues, Bitcoin will soon reverse its losing ways. And if it does, Bitcoin will go back to being the millionaire maker of choice for crypto investors everywhere.

Joerg Hiller Feb 14, 2026 11:01

ARB price prediction suggests potential recovery to $0.15 in coming weeks as technical indicators show oversold conditions, though bears remain in control below key resistance levels.

ARB Price Prediction Summary • Short-term target (1 week): $0.13-$0.14 • Medium-term forecast (1 month): $0.11-$0.17 range
• Bullish breakout level: $0.18 • Critical support: $0.11

What Crypto Analysts Are Saying About Arbitrum While specific analyst predictions are limited in recent days, earlier January forecasts from crypto analysts Tony Kim and Unusual Whales projected ARB reaching $0.25 within 3-4 weeks from their analysis date, citing bullish MACD histogram patterns and neutral RSI conditions at that time. However, current market conditions have shifted significantly since those predictions were made.

According to on-chain data platforms, Arbitrum's price action has been consolidating in a tight range, suggesting accumulation by institutional players despite the broader bearish sentiment in the Layer 2 ecosystem.

ARB Technical Analysis Breakdown ARB's current technical setup reveals a mixed but cautiously optimistic picture. Trading at $0.12, the token has gained 5.96% in the last 24 hours, breaking above its 7-day moving average of $0.11 but remaining well below longer-term averages.

The RSI at 32.48 indicates ARB is approaching oversold territory without being extremely oversold, providing room for potential upward movement. The MACD histogram showing -0.0000 suggests bearish momentum is weakening, though it hasn't turned decisively bullish yet.

Arbitrum's position within the Bollinger Bands at 0.33 indicates the price is closer to the lower band ($0.09) than the upper band ($0.18), suggesting potential for mean reversion toward the middle band at $0.13. The daily ATR of $0.01 shows relatively low volatility, which could precede a significant price movement.

Key resistance lies immediately at the current price level of $0.12, with the next significant barrier at the upper Bollinger Band of $0.18. Support is established at $0.11, aligning with both the 7-day SMA and recent trading lows.

Arbitrum Price Targets: Bull vs Bear Case Bullish Scenario If ARB breaks above the immediate resistance at $0.12 with strong volume, the next target sits at $0.13-$0.14, corresponding to the 20-day SMA area. A sustained move above $0.14 could trigger momentum toward the upper Bollinger Band at $0.18.

For this Arbitrum forecast to materialize, we need to see RSI climbing above 40 and MACD histogram turning positive. The bullish case gains strength if Bitcoin and Ethereum maintain their recent stability, providing a supportive backdrop for Layer 2 tokens.

Bearish Scenario Should ARB fail to hold the $0.11 support level, the next significant support zone appears around $0.09, coinciding with the lower Bollinger Band. A break below this level could trigger additional selling pressure toward the $0.08 region.

The bearish thesis strengthens if the broader crypto market experiences another downturn or if Arbitrum-specific negative news emerges regarding network adoption or competition from other Layer 2 solutions.

Should You Buy ARB? Entry Strategy For traders considering ARB positions, the current level around $0.12 presents a reasonable risk-reward setup. A conservative entry strategy would involve:

Buying on any dip toward $0.11 support with a tight stop-loss at $0.105. This provides approximately 2:1 risk-reward ratio targeting the $0.13-$0.14 resistance zone.

More aggressive traders might consider dollar-cost averaging between $0.11-$0.12, setting stop-losses at $0.09 to limit downside exposure. Position sizing should remain conservative given the uncertain macro environment and ARB's distance from major moving averages.

Conclusion This ARB price prediction suggests cautious optimism for the coming weeks, with potential for a move toward $0.15 if current technical consolidation resolves to the upside. However, the token remains in a longer-term downtrend, requiring patience and careful risk management.

The Arbitrum forecast becomes more constructive above $0.14, while a break below $0.11 would signal further downside pressure. Given the mixed technical signals and limited recent analyst coverage, traders should maintain moderate position sizes and clear exit strategies.

Disclaimer: Cryptocurrency investments carry significant risk. This analysis is for informational purposes only and should not be considered financial advice. Always conduct your own research and consider your risk tolerance before making investment decisions.

Image source: Shutterstock

arb price analysis arb price prediction

TL;DR Bitcoin has fallen more than 25% from its $120,000 peak, fueling debate over whether this marks another cyclical downturn or a structural shift driven by institutional adoption. Federal Reserve officials stress that BTC still behaves as a risk asset rather than digital gold.

Ted Hisokawa Feb 14, 2026 11:13

SUI Price Prediction Summary • Short-term target (1 week): $1.04-1.10 • Medium-term forecast (1 month): $1.20-1.46 range • Bullish breakout level: $1.04 • Critical support: $0.89 What Crypto...

SUI Price Prediction Summary • Short-term target (1 week): $1.04-1.10 • Medium-term forecast (1 month): $1.20-1.46 range
• Bullish breakout level: $1.04 • Critical support: $0.89

What Crypto Analysts Are Saying About Sui While specific analyst predictions from major KOLs are limited in recent trading sessions, available market analysis provides some insight into SUI's trajectory. According to blockchain.news reporting from Felix Pinkston in January, analysts had been targeting $2.20 for February, though current price action suggests this target may need revision given SUI's retreat to $0.99.

CoinCodex data indicates that Sui has been trading above their algorithmic predictions recently, suggesting the token had been performing better than expected before this recent pullback. On-chain metrics and technical analysis now point to oversold conditions that could present a buying opportunity for traders looking at SUI's medium-term potential.

SUI Technical Analysis Breakdown SUI's current technical picture presents a mixed but potentially bullish setup for patient traders. At $0.99, the token is trading significantly below all major moving averages, with the 20-day SMA at $1.10 representing immediate overhead resistance.

The RSI reading of 35.41 indicates SUI is approaching oversold territory without being extremely oversold, suggesting there may be room for further downside but also indicating potential for a bounce. The MACD histogram at 0.0000 shows bearish momentum has stalled, which often precedes trend changes.

Bollinger Bands analysis reveals SUI is positioned at 0.34, meaning it's trading closer to the lower band ($0.74) than the upper band ($1.46). This positioning typically indicates oversold conditions and potential for mean reversion toward the middle band at $1.10.

The daily ATR of $0.09 shows moderate volatility, providing reasonable risk-reward ratios for position sizing. Key resistance levels are clearly defined at $1.01 and $1.04, while support sits at $0.94 and $0.89.

Sui Price Targets: Bull vs Bear Case Bullish Scenario If SUI can reclaim the $1.04 resistance level, the next logical targets align with moving average levels. The 20-day SMA at $1.10 represents the first major target, followed by the EMA 26 at $1.16.

A sustained break above $1.16 could open the door to testing the 50-day SMA at $1.43, which coincides closely with the upper Bollinger Band at $1.46. This Sui forecast suggests potential upside of 45-47% from current levels if bullish momentum develops.

The bullish case requires volume confirmation above $1.04 and RSI moving back above 40 to signal momentum shift.

Bearish Scenario Failure to hold the $0.94 support level could trigger a test of the strong support at $0.89. A break below this level would likely accelerate selling toward the lower Bollinger Band at $0.74, representing potential downside of 25% from current levels.

The bearish scenario becomes more probable if RSI breaks below 30 and volume increases on any downward moves. Traders should watch for any breakdown below $0.89 as a signal to exit long positions.

Should You Buy SUI? Entry Strategy For traders considering SUI positions, the current price near $0.99 offers a reasonable risk-reward setup with clear technical levels for risk management.

Conservative entry strategy would wait for a break and retest of $1.04 resistance with volume confirmation. This approach reduces risk but may miss the initial bounce. Aggressive traders might consider accumulating between $0.94-0.99 with tight stops below $0.89.

Position sizing should account for the daily ATR of $0.09, allowing for normal volatility. Stop-loss levels at $0.87 (below strong support) provide approximately 12% risk from current levels, while initial targets at $1.10 offer 11% upside potential.

Risk management becomes crucial given SUI's distance from major moving averages. The 200-day SMA at $2.38 shows how far the token has fallen from longer-term trends.

Conclusion This SUI price prediction suggests cautious optimism for the medium term, with technical indicators showing oversold conditions that often precede bounces. The immediate target of $1.04-1.10 provides reasonable upside potential with defined risk levels.

However, SUI must prove it can reclaim key resistance levels before any sustained rally develops. The Sui forecast for March points toward the $1.20-1.46 range if bulls can establish momentum, but failure at current support levels could extend the downtrend toward $0.74.

Disclaimer: Cryptocurrency price predictions are speculative and based on technical analysis. Digital asset prices are highly volatile and can result in significant losses. Always conduct your own research and never invest more than you can afford to lose.

Image source: Shutterstock

sui price analysis sui price prediction

Shares of Nasdaq-listed Helius Medical Technologies (HSDT) surged nearly 15%  after the company announced a new lending program linked to staked Solana (SOL).

The company will now let institutions borrow against their staked SOL without selling or unstaking it. This move pushed investor interest higher, especially after the stock had touched record lows earlier this week.

How the Lending Program WorksHSDT partnered with Anchorage Digital and Kamino Finance to launch the program.

Institutions can keep their SOL staked, continue earning rewards, and still borrow funds. The assets remain in custody while firms access liquidity. Companies do not need to sell tokens to raise cash.

This setup helps institutions manage cash needs while holding long-term crypto investments.

Why It Matters NowSolana’s price has fallen from highs near $245 to around $83 during the broader market correction. The drop has hurt companies that hold large SOL reserves.

HSDT remains well below levels seen before it shifted to a Solana treasury strategy. The recent stock jump reflects optimism about better capital management, not a full recovery in crypto prices.

Market ImpactSeveral SOL-focused firms are adjusting their approach. Some are increasing staking operations to earn steady rewards. Others are exploring additional income strategies.

The broader crypto market still faces pressure. However, companies continue building financial tools around staking and lending. Investors reacted positively to signs that institutions are improving risk management instead of exiting the space.

For now, the stock rally signals cautious confidence as firms look for ways to strengthen their position during a volatile market.

Never Miss a Beat in the Crypto World!Stay ahead with breaking news, expert analysis, and real-time updates on the latest trends in Bitcoin, altcoins, DeFi, NFTs, and more.

FAQsCan institutions borrow against staked Solana without unstaking?

Yes. The program allows firms to keep SOL staked, earn rewards, and access liquidity without selling or removing tokens from custody.

Is this program a sign of a Solana price recovery?

Not necessarily. The stock rally reflects improved capital strategy, while SOL prices remain lower amid broader market volatility.

What does this mean for institutional crypto adoption?

It signals growing use of structured lending tools, showing institutions are refining risk management rather than exiting crypto markets.

Trust with CoinPedia:CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.

Progress around key crypto legislations in the US remains stuck in limbo, effectively capping price action as institutional capital remains on the sidelines.

After a year of blistering gains that saw Bitcoin soar from under $70,000 to an all-time high of $126,000 in October, the flagship crypto has crashed to multi-month lows.

Bitcoin’s rally last year was primarily fueled by President Trump’s return to office and a renewed political mandate to make the United States “the crypto capital of the world.”

Subsequently, a string of pro-industry appointments and legislative efforts, including the GENIUS Act for stablecoins, initially buoyed sentiment.

But market euphoria has collided with the entrenched complexities of US policymaking.

Bitcoin price is now trading below its re-election baseline, and briefly dipped to a 16-month low near $60,000 this week before stabilising in the $65,000–$68,000 range. 

Key legislations stall in the US Copy link to section

The GENIUS Act, signed into law in mid-2025, established baseline standards for fiat-backed stablecoins and was hailed as the sector’s first meaningful regulatory win. 

But with enforcement rules still pending finalisation from the Treasury and banking regulators, expected no sooner than July 2026, their market impact remains partial.

Meanwhile, broader efforts to define the contours of US crypto oversight have stalled outright. 

The CLARITY Act, designed to resolve the long-standing jurisdictional battle between the SEC and CFTC, cleared the House in 2025 but hit a wall in the Senate Banking Committee at the start of 2026.

The bill’s demise followed criticism from major industry players, including Coinbase, which withdrew support over controversial amendments targeting stablecoin yield programs. 

Banks, led by voices like Bank of America CEO Brian Moynihan, warned that such products could drain trillions from traditional deposits and destabilise smaller lenders.

Crypto firms, in turn, accused lawmakers of caving to TradFi pressure.

Senators Tim Scott and Elizabeth Warren, though ideologically distant, have found common ground in opposing the current draft, albeit for vastly different reasons.

A recent closed-door White House summit on Feb. 10, between banking titans and crypto executives, despite being described as “productive,” ultimately failed to resolve the issue of stablecoin yield, leaving the CLARITY Act’s markup indefinitely postponed.

The situation has left policymakers paralysed, with bipartisan factions now sceptical of any bill that has simultaneously alienated both Wall Street and Web3.

Crypto market impact Copy link to section

With no functional framework to regulate or expand crypto infrastructure in the US, capital has begun to migrate elsewhere.

According to data from SoSovalue, roughly $3 billion in net outflows from US-based crypto funds have occurred since the start of 2026.

Meanwhile, more than $800 billion in market cap has evaporated from the digital asset sector since January 1, according to industry trackers.

Institutional investors, particularly pension funds and endowments, are now sitting on the sidelines, unwilling to engage with a market that remains in a regulatory grey zone.

Analysts have described the current environment as directionless, a result of the disappearance of the regulatory premium that once pushed prices higher on anticipation of a mature US market.

Until lawmakers resolve key points of contention, Bitcoin is expected to remain range-bound. 

For now, Bitcoin and the broader crypto market are trading more on global macro signals and liquidity flows.

Cover image via U.Today Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

XRP reversed a three-day drop, rebounding from a low of $1.347 on Feb. 13. The recovery extended on Saturday with the XRP price trading in green.

At press time, XRP was up nearly 7% in the last 24 hours to $1.44 and up 1.79% weekly. The XRP price rebound follows the broader crypto market recovery as a lower-than-expected CPI reading helped boost the outlook for Federal Reserve interest rate cuts on the futures market.

The consumer price index for January rose 2.4% from the same time a year ago, down 0.3 percentage points from the prior month and the lowest since May 2025.

HOT Stories

You Might Also Like

The price rebound also follows a successful XRP Community Day event, which reemphasized the focus on XRP and its native ecosystem, XRP Ledger.

At the event, Ripple CEO Brad Garlinghouse reemphasized XRP as top priority, calling it a "North Star" for the company. This same view was also echoed by Ripple President Monica Long, saying XRP remains at the center of everything Ripple is building.

The event saw new announcements, including tokenization and the XRP Ledger Foundation's director.

Aviva Investors, the global asset management business of Aviva, and Ripple announced a partnership, with the intention of tokenizing traditional fund structures.

Ripple will support Aviva Investors with the initiative part of its broader effort to bring traditional financial assets with real utility to the XRP Ledger.

The XRPL Foundation announced the appointment of Brett Mollin as its new executive director.

$0.80 remains supportXRP is clinging to the support line of the descending channel pattern, increasing the risk of a breakdown, which might ultimately reach $0.80. According to Alicharts, XRP could find support at $0.80.

If XRP falls from current levels, it may drop to the $1.11 level. This is a critical level for buyers to defend, as a break below it may resume the downtrend. XRP may then fall to $1 and subsequently to $0.80.

On the other hand, if the XRP price turns up from the current level and breaks above $1.55, it suggests that it might remain inside the channel for some time. Buyers will have to achieve a close above $1.82 and $2.40 (daily MA 50 and 200) to signal a potential trend change.

📊
No votes yet – Be the first to vote

Crypto markets heated up Tuesday. XRP jumped to $0.65 while Solana hit $24.50 and meme token PEPE shocked traders with a 15% spike that nobody saw coming.

Ripple’s legal team dropped hints about wrapping up their SEC battle by month’s end, and XRP holders went wild. The token climbed from $0.60 earlier in the day as speculation ran hot about a possible settlement. Binance reported trading volumes shot up 20% compared to last week, with XRP leading the charge. John Deaton, the lawyer who’s been tracking Ripple’s case like a hawk, said on his podcast that February 28 could be the magic date. “Settlement talks are heating up,” Deaton said. “The SEC wants this wrapped up too.”

PEPE’s surge caught everyone off guard.

The meme token, which started as pretty much a joke, suddenly became Coinbase’s top gainer for the day. Trading volume exploded as retail investors piled in, ignoring warnings about volatility. Changpeng Zhao, Binance’s CEO, tweeted a reality check: “PEPE’s community-driven, but don’t get reckless. Meme coins can tank just as fast as they pump.” But his warning didn’t slow the buying frenzy. Online crypto communities on Reddit and Discord buzzed with PEPE talk, driving more FOMO buying throughout Tuesday’s session.

Solana grabbed headlines for different reasons – actual tech progress instead of hype. Solana Labs announced a strategic partnership with a major tech firm on February 12, focusing on scalability upgrades and security improvements. The news sent SOL climbing as developers and institutional investors took notice.

Kraken exchange saw Solana transactions jump 25% compared to last month. “The partnership changes everything for our ecosystem,” said Anatoly Yakovenko, Solana Labs CEO, during Tuesday’s press conference. “We’re solving the network issues that held us back.” Yakovenko’s comments resonated with the crypto community, which had been skeptical about Solana’s stability after previous outages.

And the broader market? Cautiously optimistic but jittery. See also: XRP Surges Past Resistance as Filecoin.

Bitcoin and Ethereum still dominate, but traders are branching out into altcoins hunting for bigger gains. The regulatory landscape keeps everyone on edge – governments worldwide are debating crypto policies that could reshape everything overnight. Market analysts say investor sentiment can flip in hours, not days, making volatility the only constant in this space.

Ripple’s court case remains the elephant in the room for the entire industry. Any decision will ripple through crypto markets, affecting how regulators treat digital assets going forward. XRP holders aren’t just betting on price gains – they’re betting on regulatory clarity that could unlock institutional adoption. The stakes couldn’t be higher for both Ripple and the broader crypto ecosystem.

Trading data from major exchanges paints a clear picture of shifting investor behavior. Binance, Coinbase, and Kraken all reported unusual activity patterns on Tuesday. Retail investors seem more willing to take risks on smaller altcoins, while institutional players stick to established tokens with clearer regulatory status. The divide between retail and institutional strategies has never been more obvious.

PEPE’s unexpected rise raises questions about market maturity. Some analysts worry that meme token speculation distracts from legitimate blockchain innovation. Others argue that community-driven projects represent crypto’s democratic nature. Either way, PEPE’s trading volume can’t be ignored – it’s real money moving real markets, regardless of the token’s origins.

Solana’s technological improvements come at a crucial time. The blockchain faced criticism over network outages and centralization concerns, but recent upgrades seem to address these issues. Developers are returning to build on Solana, attracted by its speed and lower transaction costs compared to Ethereum. The February 12 partnership announcement adds credibility to Solana’s comeback story. Related coverage: Ripple CTO Slams Bitcoin Technology While.

Market watchers expect more volatility ahead. Ripple’s legal resolution could trigger massive moves across multiple cryptocurrencies. Solana’s partnership could attract more institutional interest. PEPE’s meme status might fade as quickly as it appeared. The only certainty is uncertainty in crypto markets.

Neither Ripple nor Solana representatives responded to requests for additional comment by press time. PEPE, being a community-driven token, has no official spokesperson to provide statements about its recent price action.

February 13 marked a pivotal day for these three cryptocurrencies, each representing different aspects of the crypto ecosystem – regulatory battles, technological innovation, and community-driven speculation.

The Federal Reserve’s recent signals about potential interest rate adjustments have crypto traders on high alert. Lower rates historically push investors toward riskier assets like digital currencies, while rate hikes tend to cool speculative buying. Fed Chair Jerome Powell’s comments last week about “data-dependent” monetary policy left markets guessing, but crypto enthusiasts see opportunity in the uncertainty.

Meanwhile, institutional adoption continues accelerating despite regulatory fog. BlackRock’s Bitcoin ETF application remains under SEC review, and Fidelity just expanded its crypto custody services for pension funds. Traditional finance giants like JPMorgan and Goldman Sachs quietly built crypto trading desks while publicly expressing caution. The institutional money flowing into crypto infrastructure suggests big players expect digital assets to stick around, regardless of short-term price swings.

Post Views: 15

An artificial intelligence model is projecting that XRP is likely to remain subdued and trade below the $2 spot level heading into March.

Notably, the cryptocurrency has struggled in recent weeks after being impacted by the widespread market sell-off led by Bitcoin (BTC). To this end, the asset continues to trade below the $1.50 level.

Regarding the price outlook, Finbold turned to OpenAI’s ChatGPT for possible XRP price outcomes on March 1.

In this case, ChatGPT expects the token to trade between $1.35 and $1.75 on March 1, with a midpoint near $1.55 if moderately positive market conditions persist. 

In a bullish scenario, improved sentiment and higher trading volumes could lift XRP toward $1.70 to $1.90. A break above short-term resistance, potential short squeezes, and a bullish crossover on shorter-term moving averages could attract momentum traders and amplify gains.

Under a neutral outlook, XRP may consolidate between $1.35 and $1.55, reflecting range-bound trading between support near $1.30 and resistance around $1.50 without a major catalyst. 

ChatGPT noted that XRP often tracks broader cryptocurrency market trends, so a flat market could keep price action contained.

In a bearish case, sustained selling pressure and weaker market conditions could push XRP toward $1.10 to $1.30, especially if key support levels break and risk-off sentiment intensifies.

Overall, the 15-day window leading up to March 1 is relatively short in crypto markets. While sharp moves are possible, they are less likely without significant news or a shift in investor sentiment. Resistance remains clustered around $1.50 to $1.60, with support near $1.30 to $1.35, framing the near-term outlook.

XRP price prediction. Source: ChatGPT XRP fundamentals  Indeed, despite XRP relying on broader market sentiment, token investors will be banking on major Ripple-related developments to trigger possible price growth. 

In this line, the company’s aggressive expansion strategy and continued focus on ecosystem development could provide fresh fundamentals for an XRP rally, even as the token remains about 60% below its all-time high.

For instance, Chief Executive Officer Brad Garlinghouse said the company may resume acquisitions in the second half of 2026 after spending roughly $4 billion on investments, mergers, and acquisitions last year. 

While 2026 will largely focus on integrating past deals, Ripple signaled it could become more acquisitive again later in the year.

Among the major transactions were the $1.25 billion acquisition of Hidden Road, a prime brokerage platform that cleared $3 trillion annually for more than 300 institutional clients before being rebranded as Ripple Prime, and the $1 billion purchase of GTreasury, now operating as Ripple Treasury with risk management, foreign exchange, compliance, and audit capabilities.

XRP price analysis  By press time, XRP was trading at $1.43, having gained over 5% in the past 24 hours, while on the weekly timeframe, the token is up about 1%. 

XRP seven-day price chart. Source: Finbold At the current price, XRP remains below both its key moving averages, signaling prevailing downside pressure. 

The 50-day simple moving average (SMA) at $1.85 sits well above the current price, indicating that short- to mid-term momentum has weakened. More significantly, the 200-day SMA at $2.36 is substantially higher, reinforcing a broader bearish trend.

On momentum, the 14-day Relative Strength Index (RSI) stands at 37.98, which is in neutral territory but leaning toward oversold conditions. While not yet below the 30 threshold that typically signals oversold levels, the RSI suggests fading buying strength and subdued demand.

Featured image via Shutterstock